ISM004-1057D / Insilico Medicine, Fosun Pharma - LARVOL DELTA

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: InSilico Medicine Hong Kong Limited

Metastases • Monotherapy • New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma (ESMO 2023) - "ISM8207 (10 mg/kg BID) combined with rituximab resulted in synergistic effects in the B-NHL xenografts. ISM8207 was well-tolerated with favorable ADME and PK properties. Conclusions These data strongly support the clinical evaluation of ISM8207 as a novel cancer immunotherapy in TNBC and B-NHL."

IO biomarker • Breast Cancer • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • QPCT • SIRPA

Small Molecule Targeting CD47-SIRPα Pathway: Insilico Medicine Achieves its First Major Milestone in Fosun Pharma Collaboration with the Nomination of Preclinical Candidate for QPCTL (PRNewswire) - "Insilico Medicine...announced that it has used its proprietary AI platform to nominate a preclinical candidate compound (PCC) for innovative cancer immunotherapy for its QPCTL program. Notably, this is the first major milestone achieved by Insilico in the strategic collaboration with Fosun Pharma. Insilico Medicine and Fosun Pharma are working together on IND-enabling studies to advance PCCs in the QPCTL program to clinical trials. ISM004-1057D, Insilico's first PCC for its QPCTL program...Insilico is working to advance ISM004-1057D to the IND stage, and if it is achieved, Fosun Pharma would be responsible for conducting clinical trials. Both parties will share commercialization profits from the QPCTL program."

Licensing / partnership • Oncology